Increased risk of serotonin syndrome and potentiated sympathomimetic effects.
Should not be used concurrently with MAOIs or within 14 days of stopping MAOIs.
Source: G&G 14e
TCA · Antidepressant
Also known as ASENDIN
Amoxapine primarily inhibits the reuptake of norepinephrine and to a lesser extent, serotonin, thereby increasing their concentrations in the synaptic cleft. Additionally, it acts as an antagonist at 5HT2A and 5HT2C serotonin receptors.
Increased risk of serotonin syndrome and potentiated sympathomimetic effects.
Should not be used concurrently with MAOIs or within 14 days of stopping MAOIs.
Source: G&G 14e
Potentiation of adrenaline's effects.
Vasoconstrictor (adrenaline) containing LA should be avoided in patients receiving tricyclic antidepressants.
Source: KDT 7e · p365
Increased risk of cardiac conduction defects.
Source: KDT 7e · p816-835
Increased cardiotoxicity (e.g., QT prolongation).
Source: Harrison 22e · p1740
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
May increase plasma exposures of TCAs.
The possibility of drug interactions should be kept in mind until the safety of the combination is firmly established.
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-10 · House clinical team